Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection

Trial Profile

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2016 Final results (n=65) presented at The International Liver Congress™ 2016.
    • 09 Dec 2015 Status changed from not yet recruiting to completed, as reported by ClinicalTrials.gov.
    • 30 Jul 2014 Planned initiation date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top